Suppr超能文献

肝门部胆管癌切除术

Resection of hilar cholangiocarcinoma.

作者信息

Strasberg S M

机构信息

Washington School of Medicine, St. Louis, MO 63110, USA.

出版信息

HPB Surg. 1998;10(6):415-8. doi: 10.1155/1998/24893.

Abstract

OBJECTIVE

Morbidity and mortality involved in the resection of hilar cholangiocarcinoma were reviewed retrospectively. The clinicopathologic and laboratory parameters that might influence the patient's survival also were re-evaluated.

SUMMARY BACKGROUND DATA

Although much progress has been made in the diagnosis and management of hilar cholangiocarcinoma, long-term outlook for most patients remains poor. Surgical resection is usually prohibited because of its local invasiveness, and most patients can only be managed by palliative drainage. Recently, many surgeons have adopted a more aggressive resection with varying degrees of success. Several prognostic factors in bile duct carcinoma have been proposed; however, no reports have specifically focused on resected hilar cholangiocarcinoma and its prognostic survival factors using multivariate analysis.

METHODS

The clinical records and pathologic slides of 49 cases with resected hilar cholangiocarcinoma were reviewed retrospectively. Twenty clinical and laboratory parameters were evaluated for their correlation with postoperative morbidity and mortality, whereas 31 variables were evaluated for their significance with postoperative survival. Variables showing statistical significance in the first univariate analysis were included in the following multivariate analysis using stepwise logistic regression test for factors affecting morbidity and mortality and Cox stepwise proportional hazard model for factors influencing survival.

RESULTS

There were 5 in-hospital deaths, and the cumulative 5-year survival rate in 44 patients who survived was 14.9%, with a median survival of 14.0 months. Multivariate analysis disclosed that coexistent hepatolithiasis and lower serum aspartate aminotransferase levels (90 U/L) had a significant low incidence of postoperative morbidity, whereas a serum albumin of less than 3 g/dL was the only significant factor affecting mortality. Regarding survival, univariate analysis identified eight significant factors: 1) total bilirubin 10 mg/dL, 2) curative resection, 3) histologic type, 4) perineural invasion, 5) liver invasion, 6) depth of cancer invasion, 7) positive proximal resected margin, and 8) positive surgical margin. However, multivariate analysis disclosed total bilirubin > or = mg/dL, curative resection, and histologic type as the three most significant independent variables.

CONCLUSIONS

Surgical resection provides the best survival for bilar cholangiocarcinoma. An adequate nutritional support to increase serum albumin over 3 g/dL is the most important factor to decrease postoperative mortality. Moreover, preoperative biliary drainage to decrease jaundice and a curative resection with adequate surgical margin are recommended if longer survival is anticipated. Patients with well differentiated adenocarcinoma seem to survive longer compared to those with moderately or poorly differentiated tumors.

摘要

目的

回顾性分析肝门部胆管癌切除术的发病率和死亡率。同时重新评估可能影响患者生存的临床病理及实验室参数。

总结背景资料

尽管在肝门部胆管癌的诊断和治疗方面已取得很大进展,但大多数患者的长期预后仍然很差。由于其局部侵袭性,手术切除通常被视为禁忌,大多数患者只能接受姑息性引流治疗。近来,许多外科医生采用了更积极的切除术并取得了不同程度的成功。已经提出了一些胆管癌的预后因素;然而,尚无报告专门使用多变量分析来关注肝门部胆管癌切除病例及其预后生存因素。

方法

回顾性分析49例肝门部胆管癌切除病例的临床记录和病理切片。评估20项临床和实验室参数与术后发病率和死亡率的相关性,同时评估31项变量与术后生存的意义。在首次单变量分析中显示具有统计学意义的变量,纳入随后的多变量分析,采用逐步逻辑回归检验分析影响发病率和死亡率的因素,采用Cox逐步比例风险模型分析影响生存的因素。

结果

有5例院内死亡,44例存活患者的累积5年生存率为14.9%,中位生存期为14.0个月。多变量分析显示,并存肝内胆管结石和较低的血清天冬氨酸氨基转移酶水平(90 U/L)术后发病率显著较低,而血清白蛋白低于3 g/dL是影响死亡率的唯一显著因素。关于生存,单变量分析确定了8个显著因素:1)总胆红素>10 mg/dL,2)根治性切除,3)组织学类型,4)神经周围侵犯,5)肝脏侵犯,6)癌浸润深度,7)近端切缘阳性,8)手术切缘阳性。然而,多变量分析显示总胆红素≥mg/dL、根治性切除和组织学类型是三个最显著的独立变量。

结论

手术切除为肝门部胆管癌提供了最佳生存机会。提供充足的营养支持以使血清白蛋白超过3 g/dL是降低术后死亡率的最重要因素。此外,如果预期生存期更长,建议术前进行胆道引流以减轻黄疸,并进行具有足够手术切缘的根治性切除。与中分化或低分化肿瘤患者相比,高分化腺癌患者似乎生存期更长。

相似文献

1
Resection of hilar cholangiocarcinoma.肝门部胆管癌切除术
HPB Surg. 1998;10(6):415-8. doi: 10.1155/1998/24893.
9
Surgical outcomes of 230 resected hilar cholangiocarcinoma in a single centre.单中心230例肝门部胆管癌切除手术的结果
ANZ J Surg. 2013 Apr;83(4):268-74. doi: 10.1111/j.1445-2197.2012.06195.x. Epub 2012 Sep 3.
10
Surgery for hilar cholangiocarcinoma: the Leeds experience.肝门部胆管癌手术:利兹的经验
Eur J Surg Oncol. 2008 Jul;34(7):787-94. doi: 10.1016/j.ejso.2007.10.005. Epub 2007 Nov 26.

引用本文的文献

1
ASO Author Reflections: Hilar Cholangiocarcinoma.ASO作者反思:肝门部胆管癌
Ann Surg Oncol. 2021 Aug;28(8):4171-4172. doi: 10.1245/s10434-021-10115-w. Epub 2021 May 4.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验